Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Transcenta HoldingHKSE:06628 +7.06%40 Days Payable is 3,203.70 as of Dec. 2025, which is 1008% above its 10-year median of 289.24. GuruFocus rates HKSE:06628 with a GF Score™ of 40/100 and a GF Value™ of HK$0.29 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 708 Biotechnology companies, Transcenta Holding ranks better than 94.07% on this metric.
The historical rank and industry rank for Transcenta Holding's Days Payable or its related term are showing as below:
HKSE:06628'
s Days Payable Range Over the Past 10 Years
Min: 165.78 Med: 289.24 Max: 4708.08
Current: 4563.87
During the past 7 years, Transcenta Holding's highest Days Payable was 4708.08. The lowest was 165.78. And the median was 289.24.
HKSE:06628's Days Payable is ranked better than 94.07% of 708
companies
in the Biotechnology industry
Industry Median: 111.42
vs HKSE:06628: 4563.87
Transcenta Holding's Days Payable
declined
from Dec. 2024 (3,511.90) to Dec. 2025 (3,203.70).
It may suggest that Transcenta Holdingaccelerated paying its suppliers.
The historical data trend for Transcenta Holding's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06628 vs VRTX, REGN, MRNA: Days Payable Comparison
For the Biotechnology subindustry, Transcenta Holding's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Transcenta Holding Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Transcenta Holding's Days Payable distribution charts can be found below:
* The bar in red indicates where Transcenta Holding's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Transcenta Holding's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Transcenta Holding (HKSE:06628) has a Days Payable of 3,203.70 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Transcenta Holding and its competitors. This is 1008% above median its historical median of 289.24. Over the past decade, Transcenta Holding's Days Payable has ranged from 165.78 to 4,708.08. According to the industry distribution chart, Transcenta Holding ranks #42 out of 708 companies in the Biotechnology industry, placing it in the top 5.9%.
Is Transcenta Holding's Days Payable too high?
Transcenta Holding's current Days Payable of 3,203.70 is 1008% above median its 10-year median of 289.24. Over the past 10 years, this metric has ranged from a low of 165.78 to a high of 4,708.08. The Biotechnology industry median Days Payable is 111.42. Transcenta Holding's value of 3,203.70 is 2775.3% above this industry median. Based on the distribution chart, Transcenta Holding ranks #42 out of 708 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Transcenta Holding has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Transcenta Holding's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Transcenta Holding ranks #42 out of 708 companies for Days Payable. This places Transcenta Holding in the top 6% of its industry — outperforming the majority of peers. The industry median Days Payable is 111.42. Transcenta Holding's value of 3,203.70 is 2775.3% above this benchmark. Historically, Transcenta Holding's own Days Payable has ranged from 165.78 to 4,708.08 over the past decade. While the company's 10-year median is 289.24 vs. the industry median of 111.42, Transcenta Holding has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.42, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Transcenta Holding's current Days Payable of 3,203.70 is 2775.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Transcenta Holding and its competitors. For the Biotechnology industry, the median Days Payable is 111.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Transcenta Holding's current Days Payable is 3,203.70, which is 1008% above median its own 10-year median of 289.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transcenta Holding stock overvalued right now?
Based on GuruFocus' analysis, Transcenta Holding (HKSE:06628) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.29, compared to a current price of HK$0.91 — trading 213.8% above its estimated fair value. The current Days Payable is 3,203.70, which is 1008% above median its 10-year median of 289.24 and 2775.3% above the Biotechnology industry median of 111.42. Transcenta Holding's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Transcenta Holding (HKSE:06628), the current Days Payable is 3,203.70 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Transcenta Holding (HKSE:06628) Overvalued in 2026?
Based on GuruFocus' analysis, Transcenta Holding stock appears to be overvalued.
The current stock price of HK$0.91 is trading 213.8% above its estimated GF Value™ of HK$0.29.
GuruFocus considers Transcenta Holding to be Significantly Overvalued.
Key valuation signals for HKSE:06628:
Days Payable: 3,203.70 (1008% above median its 10-year median of 289.24)
GF Value™: HK$0.29 vs. price of HK$0.91 (213.8% above fair value)
Industry Position: 2775.3% above the Biotechnology median (#42 of 708)
No single metric tells the full story. See the HKSE:06628 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Transcenta Holding Ltd is a clinical-stage biopharmaceutical company with fully integrated capabilities across discovery, research, clinical development, and manufacturing, uniquely positioned to advance high-impact biologic innovations with commercial potential. The company's asset, Osemitamab (TST001), is a anti-Claudin18.2 monoclonal antibody currently advancing toward late-stage development. It is building a differentiated pipeline spanning oncology, osteoporosis, kidney disease, and autoimmune disorders. It operates in a single segment and geographically its operations are spread across Chinese mainland, United States of America, and Others with Chinese Mainland deriving the majority of revenue.
40GF Score
Get the complete analysis for HKSE:06628
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06628 has been successfully added to your 
